Matrix Gla Protein (MGP) (Middle Region) Peptide
-
- Target See all MGP products
- MGP (Matrix Gla Protein (MGP))
- Protein Region
- Middle Region
- Origin
- Human
-
Source
- Synthetic
- Application
- Blocking Peptide (BP), Immunohistochemistry (IHC), Western Blotting (WB)
- Characteristics
- This is a synthetic peptide designed for use in combination with anti-MGP antibody (Catalog #: ARP51308_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
- Purification
- Purified
-
-
- Application Notes
- Each Investigator should determine their own optimal working dilution for specific applications.
- Restrictions
- For Research Use only
-
- Format
- Lyophilized
- Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
- Concentration
- 1 mg/mL
- Buffer
- Final peptide concentration is 1 mg/mL in PBS.
- Handling Advice
- Avoid repeated freeze-thaw cycles.
- Storage
- -20 °C
- Storage Comment
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
- Target
- MGP (Matrix Gla Protein (MGP))
- Synonyms
- MGLAP Peptide, NTI Peptide, Mglap Peptide, mgp-A Peptide, MGP Peptide, LOC100136434 Peptide, mgp Peptide, matrix Gla protein Peptide, matrix Gla protein L homeolog Peptide, MGP Peptide, Mgp Peptide, mgp.L Peptide, mgp Peptide
- Background
-
MGP is associates with the organic matrix of bone and cartilage. MGP is thought to act as an inhibitor of bone formation.
Alias Symbols: GIG36, MGLAP, NTI
Protein Interaction Partner: BMP2,BMP2
Protein Size: 103 - Molecular Weight
- 12 kDa
- Gene ID
- 4256
- NCBI Accession
- NM_000900, NP_000891
- UniProt
- P08493
-